SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
07 03 2023
Historique:
received: 14 08 2020
accepted: 15 02 2023
entrez: 7 3 2023
pubmed: 8 3 2023
medline: 10 3 2023
Statut: epublish

Résumé

The pediatric extra-cranial tumor neuroblastoma displays a low mutational burden while recurrent copy number alterations are present in most high-risk cases. Here, we identify SOX11 as a dependency transcription factor in adrenergic neuroblastoma based on recurrent chromosome 2p focal gains and amplifications, specific expression in the normal sympatho-adrenal lineage and adrenergic neuroblastoma, regulation by multiple adrenergic specific (super-)enhancers and strong dependency on high SOX11 expression in adrenergic neuroblastomas. SOX11 regulated direct targets include genes implicated in epigenetic control, cytoskeleton and neurodevelopment. Most notably, SOX11 controls chromatin regulatory complexes, including 10 SWI/SNF core components among which SMARCC1, SMARCA4/BRG1 and ARID1A. Additionally, the histone deacetylase HDAC2, PRC1 complex component CBX2, chromatin-modifying enzyme KDM1A/LSD1 and pioneer factor c-MYB are regulated by SOX11. Finally, SOX11 is identified as a core transcription factor of the core regulatory circuitry (CRC) in adrenergic high-risk neuroblastoma with a potential role as epigenetic master regulator upstream of the CRC.

Identifiants

pubmed: 36882421
doi: 10.1038/s41467-023-36735-2
pii: 10.1038/s41467-023-36735-2
pmc: PMC9992472
doi:

Substances chimiques

Transcription Factors 0
Chromatin 0
Adrenergic Agents 0
SMARCA4 protein, human EC 3.6.1.-
DNA Helicases EC 3.6.4.-
Nuclear Proteins 0
SOX11 protein, human 0
SOXC Transcription Factors 0
KDM1A protein, human EC 1.5.-
Histone Demethylases EC 1.14.11.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1267

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Cancer Discov. 2022 Mar 1;12(3):730-751
pubmed: 34772733
PLoS One. 2014 Dec 12;9(12):e113800
pubmed: 25503062
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
Nat Commun. 2018 Nov 19;9(1):4866
pubmed: 30451831
Clin Cancer Res. 2009 Dec 15;15(24):7642-7651
pubmed: 19996206
Nucleic Acids Res. 1999 Mar 15;27(6):1409-20
pubmed: 10037800
Nature. 2009 Jun 18;459(7249):1005-9
pubmed: 19421193
Sci Data. 2020 Apr 14;7(1):116
pubmed: 32286315
PLoS One. 2012;7(2):e31206
pubmed: 22355346
Nat Cancer. 2022 Apr;3(4):471-485
pubmed: 35484422
Sci Adv. 2020 Jul 15;6(29):eaaz3440
pubmed: 32832616
Oncogene. 2016 Sep 29;35(39):5179-90
pubmed: 26996667
Front Mol Neurosci. 2018 Aug 03;11:252
pubmed: 30123105
Nat Genet. 2017 Sep;49(9):1408-1413
pubmed: 28740262
Nat Commun. 2010 Apr 12;1:9
pubmed: 20596238
Cancers (Basel). 2021 Sep 24;13(19):
pubmed: 34638267
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093
pubmed: 29514301
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Nucleic Acids Res. 2018 Sep 6;46(15):e91
pubmed: 29800273
Nat Genet. 2017 Aug;49(8):1261-1266
pubmed: 28650485
Nature. 2020 Apr;580(7805):669-672
pubmed: 32350470
Science. 2017 Jul 7;357(6346):
pubmed: 28684471
Nat Commun. 2017 Mar 06;8:14648
pubmed: 28262751
Br J Pharmacol. 2014 Feb;171(4):905-12
pubmed: 24125182
Nat Genet. 2012 Nov;44(11):1199-206
pubmed: 23042116
Nat Commun. 2019 Apr 4;10(1):1530
pubmed: 30948783
PLoS One. 2013;8(1):e52321
pubmed: 23308108
Cell Rep. 2022 Oct 4;41(1):111455
pubmed: 36198269
Stem Cell Reports. 2016 Nov 8;7(5):955-969
pubmed: 28157484
Cell Rep Med. 2022 May 17;3(5):100632
pubmed: 35584622
Nature. 2008 Oct 16;455(7215):967-70
pubmed: 18923523
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14094-9
pubmed: 18780787
Nature. 2012 Feb 22;483(7391):589-93
pubmed: 22367537
Methods Enzymol. 2012;513:89-112
pubmed: 22929766
Nat Genet. 2018 Sep;50(9):1240-1246
pubmed: 30127528
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Cancer Discov. 2018 May;8(5):582-599
pubmed: 29510988
Nat Genet. 2018 Apr;50(4):515-523
pubmed: 29379199
Nat Rev Cancer. 2006 Aug;6(8):593-602
pubmed: 16862190
Mol Cancer. 2022 Sep 3;21(1):175
pubmed: 36057593
Life Sci Alliance. 2021 Mar 3;4(5):
pubmed: 33658318
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Blood. 2008 May 1;111(9):4668-80
pubmed: 18299449
BMC Cancer. 2012 Jun 27;12:269
pubmed: 22738398
Nat Cancer. 2021 Jan;2(1):114-128
pubmed: 35121888
Cell Death Dis. 2013 Apr 11;4:e586
pubmed: 23579273
Mol Cancer Res. 2008 Nov;6(11):1678-90
pubmed: 19010816
Development. 2010 Mar;137(5):775-84
pubmed: 20147379
Genome Biol. 2014 Dec 03;15(12):523
pubmed: 25633159
Cancer Cell. 2006 Apr;9(4):287-300
pubmed: 16616334

Auteurs

Bieke Decaesteker (B)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium. Bieke.Decaesteker@ugent.be.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium. Bieke.Decaesteker@ugent.be.

Amber Louwagie (A)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Siebe Loontiens (S)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Fanny De Vloed (F)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Sarah-Lee Bekaert (SL)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Juliette Roels (J)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Suzanne Vanhauwaert (S)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Sara De Brouwer (S)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Ellen Sanders (E)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Alla Berezovskaya (A)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Geertrui Denecker (G)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Eva D'haene (E)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Stéphane Van Haver (S)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

Wouter Van Loocke (W)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Jo Van Dorpe (J)

Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.
Department of Pathology, Ghent University Hospital, Ghent, Belgium.

David Creytens (D)

Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.
Department of Pathology, Ghent University Hospital, Ghent, Belgium.

Nadine Van Roy (N)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Tim Pieters (T)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Christophe Van Neste (C)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Matthias Fischer (M)

Department for Experimental Pediatric Oncology, and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne, Cologne, Germany.

Pieter Van Vlierberghe (P)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Stephen S Roberts (SS)

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

Johannes Schulte (J)

Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany.

Sara Ek (S)

Department of Immunotechnology, Lund University, Lund, Sweden.

Rogier Versteeg (R)

Department of Oncogenomics, Academic Medical Center, Amsterdam, 1105, AZ, The Netherlands.

Jan Koster (J)

Department of Oncogenomics, Academic Medical Center, Amsterdam, 1105, AZ, The Netherlands.

Johan van Nes (J)

Department of Oncogenomics, Academic Medical Center, Amsterdam, 1105, AZ, The Netherlands.

Mark Zimmerman (M)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Katleen De Preter (K)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium.

Frank Speleman (F)

Department of Biomolecular medicine, Ghent University, Ghent, 9000, Belgium. Franki.Speleman@ugent.be.
Cancer Research Institute Ghent (CRIG), Ghent, 9000, Belgium. Franki.Speleman@ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH